Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia

Published:2009-08 Issue:3 Volume:146 Page:292-299
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Sutton Rosemary,Venn Nicola C.,Tolisano Jonathan,Bahar Anita Y.,Giles Jodie E.,Ashton Lesley J.,Teague Lochie,Rigutto Gemma,Waters Keith,Marshall Glenn M.,Haber Michelle,Norris Murray D.,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07744.x/fullpdf

Reference31 articles.

1. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group;Biondi;Leukemia,2000

2. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction;Brisco;Lancet,1994

3. Status of minimal residual disease testing in childhood haematological malignancies;Campana;British Journal of Haematology,2008

4. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group;Cave;New England Journal of Medicine,1998

5. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone;Choi;Blood,2007

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The results of the modified St Jude Total Therapy XV Protocol in the treatment of low- and middle-income children with acute lymphoblastic leukemia;Leukemia & Lymphoma;2023-05-10

2. The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia;HemaSphere;2023-05

3. Flow Cytometric MRD Assessment in Acute Lymphoblastic Leukemias;Indian Journal of Medical and Paediatric Oncology;2023-04-17

4. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India;Pediatric Hematology and Oncology;2023-03-17

5. Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia;BMC Cancer;2022-09-15